Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS Trial

JAMA Neurology

Volumn 73, Issue 3, 2016, Pages 308-315

  Waters, Michael F ^a   Hoh, Brian L ^a   Lynn, Michael J ^b   Kwon, Hyung Min ^c,d   Turan, Tanya N ^c   Derdeyn, Colin P ^e   Fiorella, David ^f   Khanna, Anna ^a   Sheehan, Tiffany O ^a   Lane, Bethany F ^b   Janis, Scott ^g   Montgomery, Jean ^b   Chimowitz, Marc I ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Seoul National University Boramae Hospital   (South Korea)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGIOGRAPHY; ARTICLE; BASILAR ARTERY; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INTERNAL CAROTID ARTERY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; NEUROIMAGING; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; STENT; TRANSIENT ISCHEMIC ATTACK; VERTEBRAL ARTERY; AGED; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STROKE;

AGED; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RISK FACTORS; SEX FACTORS; STROKE;

EID: 84961726889     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.4315     Document Type: Article

References (18)

1. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: A large worldwide burden but a relatively neglected frontier. Stroke. 2008;39(8):2396-2399.
2. Arenillas JF. Intracranial atherosclerosis: current concepts. Stroke. 2011;42(1)(suppl):S20-S23.
3. Wong KS, Li H. Long-Term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke. 2003;34(10):2361-2366.
4. Kasner SE, Chimowitz MI, Lynn MJ, et al; Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113(4):555-563.
5. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: The Northern Manhattan Stroke Study. Stroke. 1995;26(1):14-20.
6. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology. 2003;22(2): 106-117.
7. Chimowitz MI, Kokkinos J, Strong J, et al. The warfarin-Aspirin symptomatic intracranial disease study. Neurology. 1995;45(8):1488-1493.
8. Chimowitz MI, Lynn MJ, Turan TN, et al; SAMMPRIS Investigators. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis. 2011;20(4):357-368.
9. Turan TN, Lynn MJ, Nizam A, et al; SAMMPRIS Investigators. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. Circ Cardiovasc Qual Outcomes. 2012;5(5):e51-e60.
10. Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003.
11. Derdeyn CP, Chimowitz MI, Lynn MJ, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet. 2014;383 (9914):333-341.
12. Fiorella D, Derdeyn CP, Lynn MJ, et al; SAMMPRIS Trial Investigators. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012;43(10):2682-2688.
13. Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: TheWingspan Study. Stroke. 2007;38(5):1531-1537.
14. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardizedmethod for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol. 2000;21(4):643-646.
15. Gordon NF, Salmon RD, Franklin BA, et al. Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. AmJ Cardiol. 2004;94(12):1558-1561.
16. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316.
17. Lutsep HL, Lynn MJ, Cotsonis GA, et al; SAMMPRIS Investigators. Does the Stenting Versus Aggressive Medical Therapy Trial support stenting for subgroups with intracranial stenosis? Stroke. 2015;46(11):3282-3284.
18. Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. Stroke. 2014;45:AWP130.